General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph ...
At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...
PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...
Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider ...
While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...
Hosted on MSN29d
Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26?In 2022, Pfizer made a $5.4 billion investment in Global Blood Therapeutics and its sickle cell disease therapy Oxbryta. This September, a safety scare caused the company to pull Oxbryta from the ...
After catching up with Pfizer’s Chairman and CEO, CFO, Chief Scientific Officer and Chief Strategy and Innovation Officer at the firm’s healthcare conference, JPMorgan analyst ...
Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...
Although Pfizer is not among the drugmakers suing the government to block negotiations, it has said the program will hinder drug R&D and innovation.
Pfizer’s latest-generation pneumococcal conjugate vaccine is in line to reach more people in Latin America and the Caribbean ...
While new product launches in 2023 were underwhelming, Pfizer made significant progress in 2024, which makes the company optimistic about future performance. When asked about the visibility into ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback